A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). (2015)
Attributed to:
Understanding the autoimmune mechanism in idiopathic membranous nephropathy (IMN)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1159/000430849
PubMed Identifier: 26087670
Publication URI: http://europepmc.org/abstract/MED/26087670
Type: Journal Article/Review
Volume: 130
Parent Publication: Nephron
Issue: 3
ISSN: 1660-8151